The Delaware Supreme Court last week upheld the dismissal of a lawsuit brought by the founder and an executive of Abbott (NYSE:ABT) acquisition IDEV Technologies against venture capital shops they accused of violating their fiduciary duties by diluting their economic and voting interests. The plaintiffs in the case were Jeffrey Sheldon, who co-founded IDEV in […]
Abbott Vascular to shutter Texas plant, move 50 jobs to California
Abbott closes $310M IDEV Technologies buy
Abbott acquires IDEV Technologies, OptiMedica
Abbott (NYSE:ABT) said it agreed to acquire a pair of companies in the peripheral stent and ophthalmic space for a total of up to $710 million.
The Chicago-ares medical device company said it inked a deal worth $310 million for Webster, Texas-based IDEV Technologies and its Supera Veritas stent for treating peripheral artery disease.
VIVA 2012 roundup: Cook and IDEV release stent results
Bruker names Charles Wagner Jr. CFO | Personnel Moves
GE Healthcare begins PMA process for 3D breast scanner | Regulatory Roundup
GE Healthcare (NYSE:GE) filed the first module of its pre-market approval application for the breast tomosynthesis option of its Senographe Essential system.
The health care giant said the first submission included a device description and non-clinical information, including "phantom testing," and detector performance evaluation. The system is intended as an add-on option for the Senographe Essential to produce 3D images for screening and diagnosis of breast cancer.
PLC ramps up for RenalGuard trials | Research roundup
PLC Systems Inc. (OTC:PLCSF) announced that it will commence its pivotal U.S. trial for the RenalGuard contrast-induced nephropathy treatment.
CIN is a form of acute renal failure caused by exposure to contrast media agents during image-guided cardiology and radiology procedures.
RenalGuard’s U.S. trials have been stalled for years, which PLC officials attributed to a troubled economy and stalled funding.
FDA approves low testosterone gel from Abbott | Regulatory roundup
Abbott Laboratories (NYSE:ABT) landed FDA approval for a new testosterone-boosting product.
The company’s AndroGel 1.62% is treatment for male low testosterone levels, also know as hypogonadism, which affects nearly 14 million men in the United States, according to the company.
MassDevice Network
@MassDevice
LinkedIn
YouTube